Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Xuanwu Hospital Of Capital Medical University focuses its patent efforts in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 2 pending office actions. These actions are handled by 1 distinct examiner, which indicates a high level of concentration in the prosecution process. This workload is contained within a distinct art unit, suggesting a narrow technical focus for the pending applications.
The busiest examiner assigned to these cases is FONTAINHAS, AURORA M. This examiner is responsible for 2 busiest examiner pending office actions. Because the total number of pending office actions is the same as the busiest examiner's load, this individual is managing all active matters for the hospital. The Biotechnology & Pharmaceuticals designation implies that the subject matter involves specialized medical or biological research.
For the practitioner, having 1 distinct examiner means that the prosecution strategy can be highly tailored to a specific individual's preferences. The influence of FONTAINHAS, AURORA M is central to the success of the portfolio. Since the pending office actions are in the same art unit, the hospital can expect consistent application of examination guidelines. This streamlined structure simplifies the management of the active filings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONTAINHAS, AURORA M | 2 | 37.9% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324955 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | FONTAINHAS, AURORA M | 39d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18324955 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | FONTAINHAS, AURORA M | 39d |
| 18324952 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF | FONTAINHAS, AURORA M | 39d |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18324955 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER DURING CEREBRAL ISCHEMIC STROKE AND APPLICATION THEREOF | FONTAINHAS, AURORA M | 1675 | §101§112 | Non-Final OA | 39d | Pending | May 27, 2023 |
| 18324952 | METHODS FOR DETECTING EARLY DAMAGE OF BLOOD-BRAIN BARRIER IN ISCHEMIC STROKE AND APPLICATION THEREOF | FONTAINHAS, AURORA M | 1675 | §112 | Final Rejection | 39d | Pending | May 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial